Immunic investor relations
Witryna5 kwi 2024 · Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune … Investor Relations. IR Home; News Releases; Events and Presentations; Stock … Webcasts and presentations that have been archived are available by viewing hi… 1200 Avenue of the Americas Suite 200 New York, NY 10036, USA Phone: +1 3… Immunic Therapeutics Jessica Breu Head of Investor Relations and Communic… Immunic is privately held and supported by several renowned healthcare invest… Witryna25 kwi 2024 · Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune ...
Immunic investor relations
Did you know?
Witryna3 sie 2024 · --Immunic, Inc., a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced ... Witryna8 lut 2024 · Mersana Fourth Quarter 2024 Earnings Call. February 28, 2024 at 8:00 AM EST. Listen to webcast.
Witryna29 kwi 2016 · About Immunic. Immunic AG (www.immunic.de) is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block Th17- and Th1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of … Witryna23 lut 2024 · Immunic, Inc. (NASDAQ:NASDAQ:IMUX) Q4 2024 Earnings Conference Call February 23, 2024 8:00 AM ETCompany ParticipantsJessica Breu - Head, IR & CommunicationsDaniel Vitt - CEO, President...
Witryna3 kwi 2024 · Investor Home. Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead … Witryna5 kwi 2024 · Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and …
Witryna17 lis 2024 · Immunic, Inc. Jessica Breu Head of Investor Relations and Communications +49 89 2080 477 09 [email protected]. US IR Contact Rx Communications Group Melody Carey +1 917 322 2571 [email protected]. US Media Contact KOGS Communication Edna Kaplan +1 781 639 1910 [email protected]
WitrynaImmunic Therapeutics has raised a total of $284.4M in funding over 9 rounds. Their latest funding was raised on Oct 10, 2024 from a Post-IPO Equity round. Immunic Therapeutics is registered under the ticker NASDAQ:IMUX . Immunic Therapeutics is funded by 21 investors. Vivo Capital and RTW Investments are the most recent … highland surfacingWitryna8 mar 2024 · Archived Events. Date. Event Details. Mar 8, 2024 10:30 AM EST. 43rd Annual Cowen Health Care Conference. Listen to webcast. Feb 6, 2024 4:30 PM EST. Arrowhead Pharmaceuticals 2024 First Quarter Results. Listen to webcast. highland surfacing facebookWitryna1 wrz 2024 · Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Head of Investor Relations and Communications at Immunic, will … highland support project richmond vaWitrynaNeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for chronic liver and related metabolic diseases. NeuroBo has clinical programs targeting non-alcoholic steatohepatitis (NASH), obesity, and Type 2 diabetes. Our strategic partner and the largest shareholder, Dong-A ST … highland surgeryWitryna23 lut 2024 · /PRNewswire/ -- Immunic, Inc. (NASDAQ: ... Head of Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx … how is national debt repaidWitryna3 mar 2024 · We disclaim any obligation to supplement or update the information in these press releases. Year. 2024. March 27, 2024. Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs) March 23, 2024. Incyte Provides Regulatory Update on Ruxolitinib … highland surgical associates milton maWitryna26 lut 2024 · /PRNewswire/ -- Immunic, Inc. (Nasdaq: ... Head of Investor Relations and Communications +49 89 2080 477 09 [email protected] US IR Contact Rx … how is nat from gogglebox